HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pancreatic triacylglycerol lipase deficiency — Clinical Guidelines

Overview

Pancreatic triacylglycerol lipase deficiency encompasses rare genetic disorders characterized by impaired triglyceride breakdown, primarily due to deficiencies in lipoprotein lipase (LPL) or lysosomal acid lipase (LAL). These deficiencies lead to severe hypertriglyceridemia and multi-organ involvement, including hepatic and cardiovascular complications. 1 4 9

Diagnosis

Clinical Presentation: Milky serum, eruptive xanthomas, hepatosplenomegaly, lipemia retinalis, elevated cholesterol and triglycerides. 1

Genetic Testing: Identification of specific mutations in LPL or LAL genes.

Laboratory Tests: Elevated plasma triglyceride levels, low HDL-C, and elevated transaminases. 2 3

Screening Criteria: For LAL deficiency, consider high LDL-C, low HDL-C, and elevated transaminases; ≥3 criteria from established screening tools may warrant further investigation. 2 3

Management

Dietary Interventions: Strict dietary fat restriction, medium-chain triglycerides (MCT) supplementation. 1

Pharmacological Treatments: Fibrates to reduce triglyceride levels. 1

Monitoring: Regular lipid profile and liver function tests to manage complications.

Special Populations

Pediatrics: Early infancy presentations require prompt diagnosis and intervention; dietary and pharmacological management can be effective. 1 3

Comorbidities: Consider underlying disorders when high LDL-C levels are identified, as some may not be due to LAL deficiency. 2

Key Recommendations

Genetic Testing for Suspected Cases: Initiate genetic workup in infants with clinical features suggestive of LPL or LAL deficiency to confirm diagnosis. (Evidence: Moderate 1 3)

Dietary Management: Implement strict dietary fat restriction and MCT supplementation in pediatric patients to manage hypertriglyceridemia effectively. (Evidence: Moderate 1)

Pharmacological Support: Consider fibrates for adjunctive therapy in patients with persistent hypertriglyceridemia despite dietary modifications. (Evidence: Weak 1)

References

1 Behera JR, Pattanaik S, Jain MK. An Infant with Milky Serum and a Rare Mutation. Indian pediatrics 2020. link 2 Draijer LG, Bosch AM, Wiegman A, Sjouke B, Benninga MA, Koot BGP. Screening for lysosomal acid lipase deficiency: A retrospective data mining study and evaluation of screening criteria. Atherosclerosis 2018. link 3 Reynolds TM, Mewies C, Hamilton J, Wierzbicki AS. Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. Journal of clinical pathology 2018. link 4 Mohandas MK, Jemila J, Ajith Krishnan AS, George TT. Familial chylomicronemia syndrome. Indian journal of pediatrics 2005. link 5 Auwerx JH, Babirak SP, Fujimoto WY, Iverius PH, Brunzell JD. Defective enzyme protein in lipoprotein lipase deficiency. European journal of clinical investigation 1989. link 6 Bernbäck S, Hernell O, Bläckberg L. Purification and molecular characterization of bovine pregastric lipase. European journal of biochemistry 1985. link 7 Chuang MY, Wong L, Gallaher WR, Thompson JJ, Roheim PS. Production and characterization of a monoclonal antibody to dog hepatic lipase. Biochimica et biophysica acta 1985. link90254-1) 8 Olivecrona T, Bengtsson G. Immunochemical properties of lipoprotein lipase. Development of an immunoassay applicable to several mammalian species. Biochimica et biophysica acta 1983. link90230-8) 9 Miller R, Bialer MG, Rogers JF, Jonsson HT, Allen RV, Hennigar GR. Wolman's disease: report of a case, with multiple studies. Archives of pathology & laboratory medicine 1982. link 10 Chu P, Miller AL, Mills GL. Assay of an activator for lipoprotein lipase. Clinica chimica acta; international journal of clinical chemistry 1976. link90068-1)

Pancreatic triacylglycerol lipase deficiency